Assembly Biosciences, Inc. (NASDAQ:ASMB) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Assembly Biosciences, Inc. (NASDAQ:ASMB) has earned an average recommendation of “Moderate Buy” from the eight brokerages that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, six have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $45.60.

Several analysts have issued reports on the stock. UBS Group assumed coverage on shares of Assembly Biosciences in a research report on Tuesday, September 1st. They issued a “buy” rating and a $52.00 price objective for the company. HC Wainwright restated a “buy” rating and issued a $50.00 target price on shares of Assembly Biosciences in a research note on Tuesday, August 18th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Assembly Biosciences in a report on Friday, July 17th. Mizuho set a $53.00 price objective on shares of Assembly Biosciences in a report on Tuesday, September 1st. Finally, Zacks Research upgraded shares of Assembly Biosciences from a “hold” rating to a “strong-buy” rating in a report on Thursday, August 20th.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the business. Informed Momentum Co LLC boosted its holdings in Assembly Biosciences by 1.6% in the fourth quarter. Informed Momentum Co LLC now owns 29,523 shares of the biopharmaceutical company’s stock valued at $1,004,000 after purchasing an additional 451 shares during the last quarter. ADAR1 Capital Management LLC increased its holdings in Assembly Biosciences by 4.2% during the 4th quarter. ADAR1 Capital Management LLC now owns 19,747 shares of the biopharmaceutical company’s stock worth $672,000 after purchasing an additional 800 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Assembly Biosciences by 0.9% in the 4th quarter. Geode Capital Management LLC now owns 131,307 shares of the biopharmaceutical company’s stock valued at $4,468,000 after purchasing an additional 1,212 shares in the last quarter. Arrowstreet Capital Limited Partnership raised its position in shares of Assembly Biosciences by 4.3% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 39,446 shares of the biopharmaceutical company’s stock valued at $1,095,000 after purchasing an additional 1,634 shares in the last quarter. Finally, Bank of America Corp DE raised its position in shares of Assembly Biosciences by 6,382.7% in the 3rd quarter. Bank of America Corp DE now owns 3,371 shares of the biopharmaceutical company’s stock valued at $86,000 after purchasing an additional 3,319 shares in the last quarter. Institutional investors and hedge funds own 19.92% of the company’s stock.

Assembly Biosciences Price Performance

Shares of NASDAQ ASMB opened at $35.28 on Wednesday. Assembly Biosciences has a 1-year low of $20.23 and a 1-year high of $39.71. The company has a market capitalization of $718.30 million, a price-to-earnings ratio of 34.59 and a beta of 1.13. The business has a 50-day moving average of $29.55 and a 200-day moving average of $28.31.

Assembly Biosciences (NASDAQ:ASMB) last announced its earnings results on Thursday, August 13th. The biopharmaceutical company reported ($0.20) EPS for the quarter, beating the consensus estimate of ($0.72) by $0.52. The business had revenue of $13.37 million for the quarter, compared to the consensus estimate of $8.60 million. Assembly Biosciences had a negative return on equity of 0.02% and a negative net margin of 0.06%. Research analysts expect that Assembly Biosciences will post 2.28 EPS for the current fiscal year.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.